Protocol for the MERINO study: A randomized placebo-controlled trial assessing the efficacy, safety, and cost-effectiveness of methotrexate in people with erosive hand osteoarthritis
- PMID: 39807424
- PMCID: PMC11728867
- DOI: 10.1016/j.ocarto.2024.100558
Protocol for the MERINO study: A randomized placebo-controlled trial assessing the efficacy, safety, and cost-effectiveness of methotrexate in people with erosive hand osteoarthritis
Abstract
Objective: Previous studies on the efficacy of methotrexate in people with hand osteoarthritis (OA) have shown conflicting results. The MERINO trial aims to investigate the efficacy and safety of methotrexate in people with painful inflammatory erosive hand OA.
Design: In total 163 participants with erosive hand OA, synovitis by ultrasound, and finger joint pain of 40-80 mm on a visual analogue scale (VAS) will be recruited from a rheumatology outpatient clinic. Participants are randomized 1:1 to receive either encapsulated oral methotrexate 20 mg/week or placebo for 12 months in a double-blind manner. The primary endpoint is VAS finger joint pain at 6 months. Key secondary outcomes are hand function by the Australian/Canadian hand index (AUSCAN) at 6 months and radiographic progression by the Verbruggen-Veys anatomical phase scoring system at 12 months. Other secondary endpoints include hand stiffness, disease activity, health-related quality of life, grip strength, clinical joint counts, synovitis by ultrasound and MRI, bone marrow lesions by MRI, cost-effectiveness, and symptoms in knees and hips. Adverse events will be recorded. The primary analysis will be performed on full analysis set.
Conclusions: The findings of this trial will be clinically relevant for patients with erosive hand OA and may influence future treatment recommendations.
Clinical trial registration: EU CT number: 2023-510523-30-00, NCT04579848.
Keywords: Erosive hand osteoarthritis; Function; Imaging; Methotrexate; Pain.
© 2024 The Author(s).
Conflict of interest statement
IKH reports consulting fees from Novartis, GSK and Grünenthal, and speaker honorarium from Abbvie, outside of the submitted work. Other co-authors report no conflicts of interest.
Figures
References
-
- Haugen I.K., Mathiessen A., Slatkowsky-Christensen B., Magnusson K., Boyesen P., Sesseng S., et al. Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype? Osteoarthritis Cartilage. 2016;24:647–654. - PubMed
-
- Haugen I.K., Bøyesen P., Slatkowsky-Christensen B., Sesseng S., Van Der Heijde D., Kvien T.K. Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann. Rheum. Dis. 2012;71:899–904. - PubMed
-
- Haugen I.K., Slatkowsky Christensen B., Bøyesen P., Sesseng S., Van Der Heijde D., Kvien T.K. Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. Ann. Rheum. Dis. 2016;75:702–708. - PubMed
-
- Mathiessen A., Slatkowsky-Christensen B., Kvien T.K., Hammer H.B., Haugen I.K. Ultrasound-detected inflammation predicts radiographic progression in hand osteoarthritis after 5 years. Ann. Rheum. Dis. 2016;75:825–830. - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical